{
    "clinical_study": {
        "@rank": "16730", 
        "acronym": "TCI-PCA", 
        "arm_group": [
            {
                "arm_group_label": "TCI-PCA", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion"
            }, 
            {
                "arm_group_label": "PCA", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous Patient-Controlled Analgesia"
            }
        ], 
        "brief_summary": {
            "textblock": "Treatment of postoperative pain with hydromorphone (a strong analgesic) using\n      patient-controlled analgesia with target concentrations in blood compared to conventional\n      patient-controlled analgesia after planed cardiac surgery"
        }, 
        "brief_title": "Postoperative Pain Therapy With Hydromorphone Using TCI-PCA", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postoperative Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age between 40 and 85 years, both genders\n\n          -  Scheduled for elective cardiac surgery involving thoracotomy and subsequent ICU stay\n\n        Exclusion Criteria:\n\n          -  Administration of other analgesics or sedatives, if not administered in stable dosage\n             for at least 14 days or if not used for premedication and surgery\n\n          -  Administration of hydromorphone in the period between screening and surgery\n\n          -  Severe hepatic or renal impairment in medical history\n\n          -  BMI \u226535 kg/m\u00b2\n\n          -  ASA \u22654"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035709", 
            "org_study_id": "TCI-PCA-001", 
            "secondary_id": "2013-002875-16"
        }, 
        "intervention": {
            "arm_group_label": [
                "TCI-PCA", 
                "PCA"
            ], 
            "description": "Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.", 
            "intervention_name": "Hydromorphone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hydromorphone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Therapy", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "state": "Bavaria", 
                        "zip": "91054"
                    }, 
                    "name": "Department of Anesthesiology, University Hospital Erlangen"
                }, 
                "investigator": {
                    "last_name": "Christian Jeleazcov, MD, Associate Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "christian.jeleazcov@kfa.imed.uni-erlangen.de", 
                    "last_name": "Christian Jeleazcov, MD", 
                    "phone": "00499131853", 
                    "phone_ext": "3901"
                }, 
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }, 
                    "name": "Department of Anesthesiology, University Hospital Erlangen"
                }, 
                "investigator": {
                    "last_name": "Christian Jeleazcov, MD, Associate Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) After Elective Cardiac Surgery", 
        "other_outcome": {
            "description": "Comparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding the amount of hydromorphone administered", 
            "measure": "Amount of Hydromorphone Administered", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 (Visit 3 on first day after surgery)"
        }, 
        "overall_contact": {
            "email": "christian.jeleazcov@kfa.imed.uni-erlangen.de", 
            "last_name": "Christian Jeleazcov, MD, Associate Professor", 
            "phone": "+49 9131 8533901"
        }, 
        "overall_official": {
            "affiliation": "Department of Anesthesiology, University Hospital Erlangen", 
            "last_name": "Christian Jeleazcov, MD, Associate Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Predictive accuracy of the \"Erlanger pharmacokinetic model\" of hydromorphone administered via TCI, TCI-PCA and conventional PCA during the early postoperative stage", 
            "measure": "Hydromorphone Plasma Concentrations", 
            "safety_issue": "No", 
            "time_frame": "Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour  for the following 17 hours after extubation"
        }, 
        "reference": {
            "PMID": "23958818", 
            "citation": "Jeleazcov C, Saari TI, Ihmsen H, Mell J, Fr\u00f6hlich K, Krajinovic L, Fechner J, Sch\u00fcttler J. Population Pharmacokinetic Modeling of Hydromorphone in Cardiac Surgery Patients during Postoperative Pain Therapy. Anesthesiology. 2013 Aug 16. [Epub ahead of print]"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Comparison between hydromorphone TCI-PCA and conventional hydromorphone PCA during the early postoperative stage regarding analgetic efficiency", 
            "measure": "Numerical Rating Score", 
            "safety_issue": "Yes", 
            "time_frame": "Day 0 (Visit 2 on day of surgery): -1, 3, 30, 90, 91, 93, 95, 97, 100 min after start of hydromorphone infusion but before extubation; one sample each hour  for the following 17 hours after extubation"
        }, 
        "source": "University of Erlangen-N\u00fcrnberg Medical School", 
        "sponsors": {
            "collaborator": {
                "agency": "German Federal Ministry of Education and Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Erlangen-N\u00fcrnberg Medical School", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}